News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Threshold Pharmaceuticals, Inc. (THLD)'s Cancer Drug Gets FDA Orphan Status, Shares Rise



3/30/2012 8:37:43 AM

Threshold Pharmaceutical Inc's experimental cancer drug received orphan status from U.S. health regulators, sending the biotechnology company's stock up as much as 6 percent in premarket trade. The orphan status, which is granted in the United States to drugs that treat diseases affecting fewer than 200,000 people, can provide a seven-year marketing exclusivity for the drug from the date of approval. The experimental drug, which was licensed to a unit of Germany's Merck KGaA in February, had received orphan status from European health regulators early this month.

Read at Chicago Tribune
Read at RTT News
Read at Reuters
Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES